Engineered chemokines, resistant to cancer-mediated post-transcriptional modifications, as drugs to improve cancer immunotherapy

O Ofer Mandelboim (The Concern Foundation Laboratories at the Lautenberg Center for Immunology and Cancer Research, Institute for Medical Research Israel Canada (IMRIC), Hebrew University-Hadassah Medical School) A Angel Porgador (The Shraga Segal Department of Microbiology, Immunology and Genetics, Ben-Gurion University of the Negev)

Article Details

Volume / Issue Vol. 122, Issue 21
Published May 27, 2025
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (2)

O

Ofer Mandelboim

The Concern Foundation Laboratories at the Lautenberg Center for Immunology and Cancer Research, Institute for Medical Research Israel Canada (IMRIC), Hebrew University-Hadassah Medical School

A

Angel Porgador

The Shraga Segal Department of Microbiology, Immunology and Genetics, Ben-Gurion University of the Negev